Takahiro Adachi

Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

Wataru Fukuokaya, Yuhei Koike, Yuji Yata et al. · International Journal of Urology · 2023 · 29 citations

Medicine, Oncology, Pharmacotherapy +17

Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan

Yosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto et al. · Journal of Cancer Research and Clinical Oncology · 2024 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab

Yusuke Yano, Takaya Ohno, Kazumasa Komura et al. · Cancers · 2022 · 19 citations · Full text

Medicine, Immunology, Oncology +17

Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma

Takuya Tsujino, Kazumasa Komura, Teruo Inamoto et al. · World Journal of Urology · 2023 · 12 citations

Medicine, Surgery, Urology +17

C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Taizo Uchimoto, Takuya Matsuda, Kazumasa Komura et al. · Targeted Oncology · 2024 · 11 citations

Medicine, Oncology, Pharmacology +14